Report Detail
Global Capecitabine Market Growth 2019-2024
- RnM3035143 |
- 27 February, 2019 |
- Global |
- 139 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine is a prescription medication used to treat breast cancer and cancer of the colon or rectum. Capecitabine belongs to a group of drugs called antimetabolites which work by interfering with DNA production, stopping cells from multiplying. The medication comes in tablet form and is usually taken twice daily, within 30 minutes after the end of a meal. The proportion of breast cancer with Handle in 2016 is about 40%, and the proportion of colorectal cancer in 2016 is about 31.94%.
Cancer clinical treatment projects have led to the increasing demand for Capecitabine. Increasing Cancer incidence across the globe, especially in the Asia-Pacific is another major factor, driving the growth of the Capecitabine market during the forecast period.
According to this study, over the next five years the Capecitabine market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Capecitabine business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Capecitabine market by product type, application, key manufacturers and key regions and countries.
This study considers the Capecitabine value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
500 mg
150 mg
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Breast Cancer
Colorectal Cancer
Stomach Cancer
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Capecitabine consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Capecitabine market by identifying its various subsegments.
Focuses on the key global Capecitabine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Capecitabine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Capecitabine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Capecitabine Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Capecitabine Consumption 2014-2024
- 2.1.2 Capecitabine Consumption CAGR by Region
- 2.2 Capecitabine Segment by Type
- 2.2.1 500 mg
- 2.2.2 150 mg
- 2.3 Capecitabine Consumption by Type
- 2.3.1 Global Capecitabine Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Capecitabine Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Capecitabine Sale Price by Type (2014-2019)
- 2.4 Capecitabine Segment by Application
- 2.4.1 Breast Cancer
- 2.4.2 Colorectal Cancer
- 2.4.3 Stomach Cancer
- 2.5 Capecitabine Consumption by Application
- 2.5.1 Global Capecitabine Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Capecitabine Value and Market Share by Application (2014-2019)
- 2.5.3 Global Capecitabine Sale Price by Application (2014-2019)
3 Global Capecitabine by Players
- 3.1 Global Capecitabine Sales Market Share by Players
- 3.1.1 Global Capecitabine Sales by Players (2017-2019)
- 3.1.2 Global Capecitabine Sales Market Share by Players (2017-2019)
- 3.2 Global Capecitabine Revenue Market Share by Players
- 3.2.1 Global Capecitabine Revenue by Players (2017-2019)
- 3.2.2 Global Capecitabine Revenue Market Share by Players (2017-2019)
- 3.3 Global Capecitabine Sale Price by Players
- 3.4 Global Capecitabine Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Capecitabine Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Capecitabine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Capecitabine by Regions
- 4.1 Capecitabine by Regions
- 4.1.1 Global Capecitabine Consumption by Regions
- 4.1.2 Global Capecitabine Value by Regions
- 4.2 Americas Capecitabine Consumption Growth
- 4.3 APAC Capecitabine Consumption Growth
- 4.4 Europe Capecitabine Consumption Growth
- 4.5 Middle East & Africa Capecitabine Consumption Growth
5 Americas
- 5.1 Americas Capecitabine Consumption by Countries
- 5.1.1 Americas Capecitabine Consumption by Countries (2014-2019)
- 5.1.2 Americas Capecitabine Value by Countries (2014-2019)
- 5.2 Americas Capecitabine Consumption by Type
- 5.3 Americas Capecitabine Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Capecitabine Consumption by Countries
- 6.1.1 APAC Capecitabine Consumption by Countries (2014-2019)
- 6.1.2 APAC Capecitabine Value by Countries (2014-2019)
- 6.2 APAC Capecitabine Consumption by Type
- 6.3 APAC Capecitabine Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Capecitabine by Countries
- 7.1.1 Europe Capecitabine Consumption by Countries (2014-2019)
- 7.1.2 Europe Capecitabine Value by Countries (2014-2019)
- 7.2 Europe Capecitabine Consumption by Type
- 7.3 Europe Capecitabine Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Capecitabine by Countries
- 8.1.1 Middle East & Africa Capecitabine Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Capecitabine Value by Countries (2014-2019)
- 8.2 Middle East & Africa Capecitabine Consumption by Type
- 8.3 Middle East & Africa Capecitabine Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Capecitabine Distributors
- 10.3 Capecitabine Customer
11 Global Capecitabine Market Forecast
- 11.1 Global Capecitabine Consumption Forecast (2019-2024)
- 11.2 Global Capecitabine Forecast by Regions
- 11.2.1 Global Capecitabine Forecast by Regions (2019-2024)
- 11.2.2 Global Capecitabine Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Capecitabine Forecast by Type
- 11.8 Global Capecitabine Forecast by Application
12 Key Players Analysis
- 12.1 Roche
- 12.1.1 Company Details
- 12.1.2 Capecitabine Product Offered
- 12.1.3 Roche Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 Roche News
- 12.2 Teva
- 12.2.1 Company Details
- 12.2.2 Capecitabine Product Offered
- 12.2.3 Teva Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 Teva News
- 12.3 Mylan
- 12.3.1 Company Details
- 12.3.2 Capecitabine Product Offered
- 12.3.3 Mylan Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 Mylan News
- 12.4 Hikma
- 12.4.1 Company Details
- 12.4.2 Capecitabine Product Offered
- 12.4.3 Hikma Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 Hikma News
- 12.5 Hengrui Medicine
- 12.5.1 Company Details
- 12.5.2 Capecitabine Product Offered
- 12.5.3 Hengrui Medicine Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Hengrui Medicine News
- 12.6 Cipla
- 12.6.1 Company Details
- 12.6.2 Capecitabine Product Offered
- 12.6.3 Cipla Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Cipla News
- 12.7 Reliance Group
- 12.7.1 Company Details
- 12.7.2 Capecitabine Product Offered
- 12.7.3 Reliance Group Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 Reliance Group News
- 12.8 Hetero
- 12.8.1 Company Details
- 12.8.2 Capecitabine Product Offered
- 12.8.3 Hetero Capecitabine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.8.4 Main Business Overview
- 12.8.5 Hetero News
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Capecitabine . Industry analysis & Market Report on Capecitabine is a syndicated market report, published as Global Capecitabine Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Capecitabine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
